Information regarding "Lokelma voucher" is not available in the provided context.
What is Lokelma?
Lokelma, whose active ingredient is sodium zirconium cyclosilicate, is a medication used to treat hyperkalemia [1]. Hyperkalemia is a condition characterized by elevated levels of potassium in the blood [1]. Lokelma works by binding to potassium in the gastrointestinal tract, thereby reducing potassium absorption and promoting its excretion [1].
When will Lokelma's patents expire?
The patent expiration dates for Lokelma are not specified in the provided information. Information on drug patent expirations, including for Lokelma, can be found on resources like DrugPatentWatch.com [2].
Who makes Lokelma?
Lokelma is manufactured by AstraZeneca [1].
How does Lokelma work to lower potassium levels?
Lokelma is an orally administered agent that binds potassium ions in the gastrointestinal tract [1]. It selectively exchanges potassium for sodium and protons on its surface, effectively trapping potassium within its structure and preventing its absorption into the bloodstream [1]. This process helps to reduce serum potassium levels [1].
What are the alternatives to Lokelma for managing hyperkalemia?
Other medications used to manage hyperkalemia include patiromer and traditional ion-exchange resins like sodium polystyrene sulfonate [1]. These alternatives also work by binding potassium in the gut to facilitate its removal from the body [1].
What are the clinical trial results for Lokelma?
Clinical trials have demonstrated Lokelma's efficacy in reducing and maintaining normal serum potassium levels in patients with hyperkalemia [1]. Studies have shown significant reductions in potassium levels within the first 48 hours of treatment and sustained control over longer periods [1].
Are there patient concerns about Lokelma?
Patient concerns can vary, but typically revolve around medication effectiveness, side effects, and ease of use [3]. Specific patient concerns related to Lokelma would be detailed in patient information leaflets and discussions with healthcare providers [3].
How is Lokelma supplied and dosed?
Lokelma is supplied as a powder for oral suspension [1]. The recommended starting dose is 10 grams administered three times daily, with dosage adjustments made based on serum potassium levels and patient response [1].
What are the potential side effects of Lokelma?
Common side effects associated with Lokelma include gastrointestinal disturbances such as constipation, diarrhea, and nausea [1]. Edema, or swelling, has also been reported [1].
What is the regulatory status of Lokelma?
Lokelma has received regulatory approval in several regions, including the United States and Europe, for the treatment of hyperkalemia [1].
---
Sources:
[1] https://www.lokelma.com/
[2] https://drugpatentwatch.com/
[3] https://www.nhs.uk/medicines/lokelma/